0
Editorials: Point and Counterpoint |

Rebuttal From Dr Caironi

Pietro Caironi, MD
Author and Funding Information

FINANCIAL/NONFINANCIAL DISCLOSURES: The author has reported to CHEST the following: P. C. has received lecture honoraria from Grifols, B. Braun, and Baxter.

CORRESPONDENCE TO: Pietro Caironi, MD, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Via F. Sforza 35, 20122, Milan, Italy


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(6):1370-1371. doi:10.1016/j.chest.2016.03.049
Text Size: A A A
Published online

Extract

I read with interest the arguments of my opponents. The questions posed are undoubtedly crucial. As I have originally foreseen, in my rebuttal, I will have to discuss the available data in more details.

First, does administration of albumin improve outcomes in severe sepsis or septic shock? I agree with my opponents that we do not yet have a definitive answer. Nonetheless, the actual data available firmly suggest a beneficial effect of albumin-containing solutions, particularly during shock. The post hoc analysis of the ALBIOS trial revealed a significant 6.3% absolute reduction in 90-day mortality associated with albumin replacement in patients with shock, which remained significant even after adjustments for baseline unbalances (P = .02). Such improvement in survival remained significant even after adjustments for clinically relevant variables, when considering patients with shock as defined with a broader definition. In addition, all the meta-analyses performed reported data in favor of a beneficial effect of albumin in patients with shock. A this point, two considerations merit our attention. First, the “signal” supporting a survival benefit of albumin administration appears to refer to patients with shock and not to those without shock. Second, we should not contrast a single P value against a biological plausibility of a hypothesis. Even the analysis mentioned by my opponents as not significant and reported in the ALBIOS trial (relative risk in the albumin group during shock of 0.88 [95% confidence interval, 0.77-1.01] after adjustments for clinically relevant variables, P = .07) does not necessarily confirm the null hypothesis of the trial. In contrast, it may indicate either that the outcome chosen to test the hypothesis (mortality) may be inappropriate and other clinically relevant outcomes should be tested, or that the beneficial effect of the treatment may have a greater extent (and less variability) in specific patient subcategories.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543